Strive Asset Management LLC Invests $439,000 in Pfizer Inc. (NYSE:PFE)

Strive Asset Management LLC bought a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 16,560 shares of the biopharmaceutical company's stock, valued at approximately $439,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Retirement Wealth Solutions LLC acquired a new stake in Pfizer during the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer in the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. acquired a new position in shares of Pfizer in the 4th quarter worth approximately $27,000. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer during the 4th quarter worth approximately $28,000. Finally, Noble Wealth Management PBC acquired a new stake in Pfizer during the 4th quarter valued at $31,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. UBS Group increased their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. Finally, Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Stock Up 1.0%

NYSE:PFE opened at $22.83 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The stock's fifty day simple moving average is $23.65 and its 200-day simple moving average is $25.34. The firm has a market capitalization of $129.77 billion, a P/E ratio of 16.19, a P/E/G ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business's quarterly revenue was down 7.8% compared to the same quarter last year. During the same period last year, the firm posted $0.82 earnings per share. Equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.54%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio is presently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.